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1 
INTRODUCTION 
 
Cancer and the neoplastic cell 
 
Cancer is a class of diseases characterized by the pathological generation 
of abnormal cells.  The cancer begins as a localized growth that may spread 
throughout the body by the circulatory and lymphatic pathways.  The poorly 
regulated cell division is caused by damage to the DNA and to mutations in genes 
that control cell division.  Several mutations are required to turn a cell completely 
neoplastic, meaning that the transition from a normal cell to a cancerous 
(neoplastic) one can be a gradual process sometimes requiring years.  Thus, each 
cancer is the end result of multiple changes within a single cell lineage that have 
taken place during the life of the affected cell or even within the germ line of the 
host.  The critical biological changes within the cell that accompany its neoplastic 
transformation involve an altered response to mechanisms that control cell 
growth, differentiation, and senescence.  Although there are many types of cancer, 
depending on the cell type of origin (connective tissue, hematopoietic tissue, or 
epithelial tissue), each grows and spreads in its own way and causes its own set of 
symptoms.  
Cancer cells have many key behaviors that differentiate them from normal 
cells.  One characteristic of the neoplastic cell is a reduced dependence on signals 
from other cells for its growth, survival, and division. Often, this is because they 
contain mutations in components of the cell signaling pathways through which the 
cells respond to such social cues.  Neoplastic cells also have prolonged survival 
rates and are less prone to kill themselves by apoptosis than non-cancerous cells. 
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This aversion to suicide is often caused by mutations in genes that regulate the 
intracellular death program.  A third characteristic of neoplastic cells is their 
ability to proliferate indefinitely.  Most normal human somatic cells will divide 
only a limited number of times in culture, after which they permanently stop 
because the telomeres on the ends of the chromosomes become too short.  Cancer 
cells typically break through this barrier by reactivating production of the 
telomerase enzyme that maintains telomere length.   
In addition, neoplastic cells are often genetically unstable, because they 
have a greatly increased mutation rate and often have an impaired ability to repair 
damaged DNA.   They can become invasive by changes in cell-adhesion 
molecules that hold normal cells in their proper place, by generating enzymes that 
allow them to invade through tissues, and by acquiring the ability to move.  
Lastly, cancer cells can often survive and proliferate in secondary tissues to form 
metastases, whereas most normal cells do not migrate from their original position 
to other sites in the organism.  
Once cells have converted into the neoplastic phenotype, they can become 
invasive and often even metastatic.  This invasive property allows them to 
penetrate their surrounding normal tissue barriers and move to a new location 
within the body, producing secondary tumors.  This establishment of secondary 
tumors in the body is known as metastasis and proceeds through a clearly defined 
cascade of events.  The first step of the cascade is the enzymatic digestion of the 
basement membrane, which allows the cell access to connective tissue and an 
avenue to detach from the primary tumor (McKinnell et al., 1998).  The ability of 
a cell to detach and move is a fundamental property that malignant cancer cells 
exhibit.  After the cells detach from the primary tumor, they have the ability to 
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move and invade a secondary location.  The invasion of the cell into an adjacent 
tissue depends on the motility of the cell.  Cancer cells can disseminate via 
capillary and lymphatic vessels (McKinnell et al., 1998).  Once inside the 
capillaries, the cancer cells have the ability to adhere to one another, as well as to 
lymphocytes and platelets, forming emboli that can be stabilized by fibrin clotting 
(McKinnell et al., 1998).  The circulating cancer cells can arrest at a secondary 
location and grow at that site completing the dissemination of malignant cells.  
Metastasis of cancer accounts for much of its lethality.  Interruption of any of the 
steps of the cascade has the potential to disrupt the malignant spread and limit the 
malignant pathology.   In cancer, because cell production is not balanced with cell 
loss, the cell population increases in number.   Genetic instability leads to the 
generation of diverse cell variants, some of which may be able to metastasize to 
new locations. The lungs and the liver are the two most common sites for 
metastasis in the human body.  Once in a new site, a cell must again penetrate the 
basement membrane of the blood vessel and establish itself in the new tissue, for 
its own growth and survival. 
 
The Cell Cycle and its Regulation 
 
 The cell cycle is a sequence of duplication and division of the cell.  The 
function of the cycle is to duplicate DNA in the chromosomes and then precisely 
distribute the copies into genetically identical daughter cells. The cell cycle 
includes the manufacturing of DNA synthesis enzymes, the doubling of DNA, the 
synthesis of mitosis proteins, and then mitosis--the cell division. The period 
between one M phase (mitosis and cytokinesis) and the next M phase is called 
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interphase.  Interphase is divided into the remaining three phases of the cell cycle.  
The cycle begins with G
1
 and ends each round with a doubling of the cell.  The G
1
 
phase is the first of the four stages of the cell cycle in which new organelles are 
synthesized and DNA synthesis enzymes are manufactured.  This phase is 
remarkably longer than other phases because the daughter cells remain in G
1
 until 
they receive a stimulus to enter the S phase (Alberts et al., 2004).  The S phase is 
the synthesis stage in which nuclear DNA is replicated.  At the end of this stage, 
the cell contains two complete sets of DNA.  The G
2
 phase follows the S phase 
and is a relatively short, pre-mitotic phase.  Through internal biochemical 
changes, RNA and other specialized proteins are produced that will aid in the 
process of mitosis.  The M phase is the final stage of the cell cycle and is a 
continuous process of cell division.  However, it can be divided into four sub-
phases that are marked by unique events. 
 The first event of mitosis occurs in prophase, in which the chromatin is 
transformed into chromosomes, with each chromosome composed of a pair of 
filaments called chromatids (Alberts et al., 2004).  Also during prophase, the 
nuclear membrane disappears.  During metaphase, the second phase of mitosis, 
the chromosomes align between the centrioles at the equatorial plate.  They are 
positioned in such a way that when the chromatids separate, each daughter cell 
will have a complete set of chromosomes.  Anaphase, the third phase, is marked 
by the separation of the sister chromatids and the formation of two daughter 
chromosomes, in which each chromosome is pulled toward the pole that it faces.  
The contractile ring also assembles during anaphase.  During the final stage of 
mitosis, telophase, the two sets of daughter chromosomes arrive at the poles of the 
spindle, the nuclear membrane reforms, the chromatin expands, and the cytoplasm 
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divides.  It is this stage in the process, when the cytoplasm divides, that is the 
focus of my research.  This step, called cytokinesis, includes the furrowing of the 
cell, in which the contractile ring pinches off to place one nucleus in each cell.  
With the accomplishment of this step, two new daughter cells identical to the 
parent cell have been formed.   
 Progress through the cell cycle is achieved by two different cell cycle 
control mechanisms.  These two mechanisms ensure correct advancement through 
the cell cycle by regulating the cell cycle machinery.  The first type of control 
involves a series of phosphorylations by kinase enzymes and dephosphorylations 
by phosphatases that activate or inactivate proteins and complexes that initiate 
and regulate phases of the cell cycle.  These kinases that participate in 
phosphorylation combine with cyclins to become enzymatically active.  The 
activation/de-activation of these cyclin-kinase complexes trigger and help time 
various cell cycle events (Alberts et al., 2004).     
A second type of cell cycle regulation is checkpoint control.  It is not an 
essential part of the cell cycle, but is more supervisory.  Specific checkpoints 
throughout the cycle sense flaws in critical events of the cycle.  If one of the steps 
is delayed, or a flaw is detected, such as abnormal size, the control system will 
delay the activation of the next steps until the intracellular and extracellular 
conditions are favorable (Collins et al., 1997).  There are two such checkpoints in 
the cell cycle that serve as molecular brakes.  The first checkpoint lies in the G
1
 
phase and detects damage of the DNA.  If the cell arrests in this phase, the cell 
has time to repair the damaged DNA before replicating it in the S phase.  Another 
important cell-cycle checkpoint occurs in mitosis to ensure that all of the 
chromosomes are appropriately attached to the mitotic spindle.  If not all of the 
 
 
6 
chromosomes are attached to the spindle, the cell could proceed through mitosis 
with the chromosomes unevenly segregating to the poles of the cell.  With both of 
these checkpoints in the cell cycle, mutations and potential damage can be 
averted.  Thus, the cell cycle’s control system regulates and monitors the 
completion of critical events and can delay the progression, if necessary.  
There are also additional checkpoints within the cell cycle, independent of 
the regulation of cell cycle machinery, which control such things as the actin 
cytoskeleton.  According to Nakaseko and Yanagida (2001), cells have the ability 
to keep track of their actin cytoskeleton; if it is defective, the mitotic spindle 
during mitosis will become incorrectly oriented and the cell will suppress 
subsequent phases of cell division.  The mitotic spindle, which serves to move the 
duplicated chromosomes apart during mitosis (Alberts et al., 2004), has its own 
separate checkpoint, which has been previously mentioned. Though defects in the 
mitotic spindle are associated with a checkpoint of the actin cytoskeleton, the two 
checkpoints are independent.  What and how the actin cytoskeleton checkpoint 
monitors has not been completely determined.  It is known that this checkpoint 
has the ability to block normal separation of sister chromatids, which can halt 
progression in the cell cycle, until the organization is correct.  However, not much 
is known about the exact mechanism by which actin affects the spindle 
orientation.   It has been proposed that when the actin-based cytoskeleton 
becomes damaged or disorganized, this somehow results in the spindle becoming 
misoriented, which in turn activates the Sty1/Spc1 protein (Nakaseko and 
Yanagida, 2001).  The Sty1/Spc1 protein is a mitogen-activated protein kinase 
that phosphorylates another protein called Atf1, which is involved in a stress-
activated protein kinase pathway.  While the exact mechanism for this is not 
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known, it is clear that this stress-activated pathway is a key component of the 
actin-dependent mitotic checkpoint.  The ultimate result of this pathway is a 
failure to segregate the duplicate chromosomes, which like any other checkpoint, 
delays cell division until the organization becomes corrected.   
Cell volume is additionally regulated and controlled by specific pathways 
and points in the cell cycle.  In eukaryotic cells, growth is regulated by 
extracellular growth factors in both gap phases, G
1
 and G
2
, of the cell cycle.  
While there is no definite cell-size checkpoint, there is a system that regulates and 
maintains cell size that is related to the process of S phase initiation (Cooper, 
2004).  It has been proposed that mammalian cells initiate S phase and DNA 
replication at some relatively constant cell size (initiation mass), coupled with 
relatively invariant S and G
2 
phase times and variant interdivision times.  Thus, 
the cell cycle age at initiation of S phase will occur earlier and earlier within the 
cell cycle as the growth rate of a cell increases (or as the interdivision time 
decreases), because the cell has quickly reached the proposed initiation mass.  
Because of this, faster growing cells will have a relatively short G
1 
phase and 
become larger than average cells, making the faster growing cells divide sooner 
because they reach the initiation mass earlier. In addition, smaller than average 
cells will delay initiation until the initiation mass is achieved.  A cell that initiates 
S phase earlier in the cell cycle will have more time to increase its total mass prior 
to division, and conversely, smaller cells will delay initiation of S phase to allow 
for mass increase before the actual cell division.  According to Cooper, this 
finding suggests that normal cells must operate some sort of checkpoint in order 
to maintain a constant average cell size; the checkpoint ensures that a cell does 
not continue to grow after a certain size, until after division. While this cell-size 
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checkpoint operates to prevent cells from getting progressively bigger and bigger, 
there is presumably another checkpoint that prevents division from occurring 
before the cells have reached an adequate size, in order to prevent them getting 
progressively smaller. 
 
Cytochalasin B 
 
 Cytochalasin B is an alkaloid metabolite of the mold Helminthosporium 
dematiodeum produced by mold to kill off bacteria.  It is known to inhibit a wide 
variety of cellular movements including cytokinesis, cell locomotion, cytoplasmic 
streaming, blood clot retraction, and movements associated with developmental 
processes (Lin et al., 1973).  Brown and Spudich (1981) reported that 
cytochalasins inhibit the rate of actin assembly.  Lin, Santi, and Spudich showed 
earlier that cytochalasin B inhibits actin assembly by causing a decrease in the 
intrinsic viscosity of actin, and an altering in the morphology of the actin 
filaments, as shown in muscle and blood platelets (Lin et al., 1973).  They also 
suggested that there could be a possible cytochalasin B receptor on actin 
microfilaments.  Because they were able to show that there is a concentration 
dependence on binding of cytochalasin B to different types of cells, they 
concluded that there are at least two types of binding site for cytochalasin B, as 
shown by their results using bovine platelets, HeLa cells, bovine red blood cells, 
D. discoideum amoebae, and A. aereogenes cells (Lin et al., 1973).   Lin, Santi, 
and Spudich (1973) named these sites high and low affinity-binding sites.  
Flanagan and Lin next observed that in fact, filamentous actin (F-actin), and not 
globular actin, contained such high affinity cytochalasin B binding sites (Flanagan 
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and Lin, 1980).  This F-actin lies at the end of the filament where assembly takes 
place, blocking the assembly end (Brown and Spudich, 1981).   In our lab, we are 
making use of these observations and the previous research done on cytochalasin 
B to induce U937 leukemia cells into multinucleation.  Multinucleation is the 
process by which the actin microfilaments in cytokinesis are disrupted, resulting 
in a cell accumulating more than one nucleus.  
 
Manipulation of the cell cycle’s regulation: induction into multinucleation 
 
 Normal cells have key checkpoints in the cell cycle that signal the cell to 
either delay progression until any abnormalities are corrected, or to continue 
through the cycle with no interruption.  If cytochalasin B was used on a 
population of normal, non-neoplastic cells, the cells would halt at the second 
checkpoint and direct the cell to stop dividing.  This is due to the fact that 
cytochalasin B prevents normal cells from entering the cell cycle because it 
disrupts the actin microfilament cytoskeleton. The control system of the cell cycle 
will delay the activation of the next steps, and the cell will stop dividing 
mitotically in order to correct the shape and integrity of the actin cytoskeleton 
before allowing entry back into the cell cycle (Law and Reed, 1995).   In some 
neoplastic cells, on the other hand, actin microfilament disruption induced by 
cytochalasin B does not prevent cell cycle entry, but after completion of the cell 
cycle and nuclear replication, the absence of a functional actin cytoskeleton does 
prevent cytokinesis. The neoplastic cells have lost the key mechanism for 
controlling entry into the cell cycle, and multinucleation will result.  The 
neoplastic cell will go into the cell cycle and make DNA, but will not be able to 
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split into separate cells, thus creating multinucleation and enlargement of the 
cells.  Thus while normal cells exit the cell cycle and enter a G
0
 (resting) state, 
neoplastic cells continue nuclear division, become extremely enlarged and heavily 
multinucleated, and are also likely to contain elevated numbers of mitochondria 
per enlarged cell.   
We hypothesize that enlarged cells containing high levels of DNA and 
high mitochondrial contents may enter apoptosis more readily when they 
experience DNA or mitochondrial damage than will cells with normal amounts of 
DNA and mitochondria.  This could occur because the enlarged cells have more 
targets per cell for damage by DNA-directed agents or by agents damaging 
mitochondria. We further hypothesize that enlarged leukemia cells may be more 
susceptible to physical damage than are normal-sized leukemia cells because of 
the increased cytoplasmic volume retained by a plasma membrane with weakened 
internal cytoskeletal support.   In our research, we have found that U937 human 
promyleocytic leukemia cells that have been treated with cytochalasin B become 
heavily multinucleated, containing as many as eight or more nuclei depending on 
the length of treatment time.  U937 leukemia cells were chosen for this study for 
two main reasons.  The first characteristic of these cells that makes them ideal for 
our experiments is the fact that they do not adhere to one another, making them 
easy to count and individually to size.  Also, the U937 leukemia cells have the 
ability to grow in suspension, rather than attached to the plastic culture flask, 
again making them easier to count and size reliably.  With a high number of 
nuclei in one single cell, we think that the internal cytoskeletal support might 
weaken, and propose that sonication of the multinucleated cells may make them 
more susceptible to apoptosis-induction.  
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Ultrasound-induced cavitation 
   
 In medicine, ultrasound has been a widely used and well-established 
diagnostic and therapeutic technique for many years (Liu et al., 1998).  
Ultrasound is commonly used for soft tissue imaging because of its perceived 
safety, noninvasiveness, and low cost (Feril Jr. and Kondo, 2004).  Ultrasonic-
imaging, which uses high-frequency low-intensity ultrasound, is used to scan 
organs and visualize their size and structure.  This type of ultrasound does not 
damage the skin or sonicated organs.  At somewhat greater intensities, ultrasound 
can be used therapeutically to heat tissues deep within the body. On the opposite 
end of the frequency spectrum, low frequency and high intensity focused 
ultrasound is often used in lithotripsy, a procedure used to break up kidney stones 
within the body so that they can pass without the need for surgery (Liu et al., 
1998). 
Medical ultrasound has many other applications, including cancer therapy, 
which involves the process of acoustic cavitation (Feril Jr. and Kondo, 2004).  
Acoustic cavitation is the process by which high intensity acoustic fields in 
liquids lead to the creation and oscillation of cavities or gas bubbles (Liu et al., 
1998).   Acoustic cavitation has been shown to increase the permeability of cell 
membranes.  This form of cavitation has been used to permeabilize cell 
membranes, making it easier for materials to enter the cells without damaging 
them (Lee et al., 2004).  Others have shown that ultrasound transiently disrupts 
cell membranes facilitating the loading of drugs and genes into viable cells 
(Cochran and Prausnitz, 2001).   
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The goal of my laboratory use of ultrasound is not for drug delivery.  
Rather, it is to determine whether there is a sonic sensitivity of cells enlarged by 
treatment with cytochalasin B that might be exploitable as a potential modality in 
leukemia therapy.  Using acoustic cavitation, we have developed procedures with 
the potential to differentially target the enlarged U937 leukemia cells created by 
treatment with cytochalasin B possibly increasing their sonic sensitivity in 
comparison with untreated control cells.  This physical treatment may be 
applicable to enhancing the cytotoxic effects of microfilament agents in treatment 
of leukemia in pre-clinical animal models. 
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METHODS 
 
Cytochalasin B enlargement of U937 leukemia cells 
 
U937 leukemia, a human promyleocytic cell line, was used in this work.  
Cells were seeded at 5.0 x 10
4 
cells/ml in 20% fetal bovine serum in Iscove’s 
medium supplemented with 2% of 10,000 units penicillin and 10 mg 
streptomycin, 0.5% gentamicin sulfate, and 2 mM glutamine.  The cells were 
treated with cytochalasin B at concentrations ranging from 1.25 µM to 2.1 µM 
and were allowed to proliferate and enlarge for thirty-six hours.  After thirty-six 
hours, the cytochalasin B-treated cells were spun down in a 50 ml centrifuge tube.  
The tube consisted of 30 ml of cells placed carefully on top of 20 ml of phosphate 
buffered saline medium (PBS) at 37˚C.  The tube was spun for two and a half 
minutes at 20 G.   The size distribution and cell number of the enlarged, 
multinucleated cells were determined with a hemocytometer using the trypan blue 
dye exclusion test procedure and with a Model Z1 Beckman-Coulter Particle 
Counter for both the supernatant and precipitate.  This procedure is outlined 
below.  Figures 1 and 2 below show (without trypan blue) a population of control 
U937 leukemia cells in a hemocytometer at 100X as well as after treatment with 
cytochalasin B. 
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Figure 1: A population of un-treated control U937 leukemia cells. 
 
 
 
 
 
 
 
 
Figure 2: A population of cytochalasin B treated U937 leukemia cells. 
 
 
Filtration and separation of cells 
 
 The precipitated enlarged CB-treated cells were then filtered through 
nylon mesh sieve to separate the enlarged, multinucleated cells from the 
unenlarged, mononuclear cells.  A 4.5 cm filter was used fitted with 20 µ nylon 
mesh for the sieve.  A 12.5 ml aliquot of cell suspension was added to the sieve 
and was then allowed to filter until the flow of the cell suspension through the 
filter slowed to one drop a minute.  The filtrate was then removed and saved in a 
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25 ml tube to later determine its size distribution.   The trapped cells on the sieve 
were re-suspended and washed in 5 ml of warm equilibrated medium.  Ten ml of 
additional cell suspension was added to the sieve and was filtered as above.  The 
trapped washed cells were re-suspended once again after the second 10 ml was 
filtered.  The filtrate and trapped cells were counted and sized using the 
hemocytometer and Coulter Counter.  Both of these procedures are outlined 
below.     
 Results from this separation procedure (see Results) provided experience 
with ways to improve the separation of the enlarged cells from normal sized cells.    
The filtration procedure was improved based on my results with the 20 µ nylon 
mesh separation.  Dr. Thomas Fondy designed a cell separation procedure to 
better separate the enlarged, multinucleated cells from the mononucleated cells 
for use in the sonication experiment below.  For this separation procedure, U937 
leukemia cells were seeded at 3.4 x 10
4 
cells/ml in 20% fetal bovine serum in 
Iscove’s medium and were treated with cytochalasin B at a concentration of 1.25 
µM and allowed to proliferate and enlarge for thirty-six hours.  Twenty-four ml of 
the cells were centrifuged on top of 30 ml of warm PBS in a 50 ml centrifuge tube 
at 20 G for 3 minutes.  The upper 40 ml were removed and saved and the bottom 
10 ml fraction was saved as the 20G precipitate.   
A 19 µ nickel porated sieve was placed inside a crystallizing dish and cold 
sterile PBS was added to 0.5 cm above the top of the sieve.  The 10 ml fraction 
from the 20G precipitate was added to the sieve and was allowed to settle in a 
refrigerator for 30 minutes.  The upper fraction from the sieve (46 ml of cells in 
PBS suspension) was recovered.  Ten additional ml of PBS was added to the sieve 
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and the 46 ml recovered was re-sieved and allowed to settle in a refrigerator for 
30 minutes.  From atop the sieve, 60 ml was recovered and saved as the trapped 
fraction and 42 ml was recovered from the bottom of the sieve and saved as the 
filtrate.  The trapped fraction was centrifuged in two 50 ml centrifuge tubes at    
20 G for 3 minutes.  The upper 30 ml from each tube was removed, which left 
500 µl in the bottom of the two tubes.  To the 500 µl, 5 ml of 20% FBS in 
Iscove’s medium was added to both tubes and they were combined to give a total 
of 11 ml.  Ten ml was taken to form the final trapped fraction, which was diluted 
with 11 ml of 20% FBS in Iscove’s medium to give 21 ml of 1.95 X 10
4
 viable 
cells/ml for use in the sonication experiment.   
  
 
Ultrasonic disruption 
 
 
Once the cells had been separated through use of the sieve, the cells were 
then subjected to ultrasound.  To create the ultrasound delivering apparatus, an 
Omega pro lab timer was connected to an E/MC model 250 ultrasonic bath 
cleaner with a measured mean output of 0.77 watts (see Appendix E).  The 
ultrasound bath was filled with 250 ml of distilled water at 37˚C.  A ring stand 
was also used to hold the tubes exactly at the focus point of the sonicator.  
Trapped cells were suspended at 2.0 x 10
9
 viable cells/ml in 20% FBS with 
Iscove’s medium.  Two ml aliquots were placed in 8 ml sterile tubes (100 mm x12 
mm).  The tubes were then sonicated at 0, 2, 4, 6, 8, and 10 seconds and were 
done in duplicate.  Un-enlarged and untreated leukemia cells at 2.0 x 10
4
 viable 
cells/ml were used as the control and were sonicated at the same lengths of time 
as the CB-treated trapped fraction, as well as being done in duplicate.  Each tube’s 
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sample was gently re-suspended and was placed in the water so the 2 ml sample 
was completely submerged.  After all of the tubes had been sonicated, samples 
were taken from each tube for hemocytometer counts to determine cell viability 
and re-growth (see procedure below).   
 
Determining cell viability 
 
 Determining cell viability of the U937 population was done using a trypan 
blue dye exclusion test coupled with a hemocytometer.  Trypan blue is one of 
several stains used in this method, which is based upon the principle that viable 
cells do not take up the dye whereas non-viable cells do.  This occurs because 
cells with an intact membrane are able to exclude the dye while cells without an 
intact membrane take up the trypan blue.  Therefore, all cells that exclude the dye 
are scored as viable.  The test was performed by mixing 50 µl of cell suspension 
with an equal amount of 0.4% trypan blue stain in isotonic saline.  After the stain 
was added, the solution was mixed thoroughly and 12 µl of the mixture was 
transferred to each of the two counting chambers of a hemocytometer.    By 
means of a light microscope, the cells were recorded as either small (<20 µ) or big 
(>20 µ) in size using the eyepiece reticle, and whether they were viable or not.  
Using a trypan blue viability form created in Microsoft Excel and developed by 
Dr. Thomas Fondy (see Appendix A), the total percent viability and cell size were 
calculated for the population.  Figure 3 below shows an example of a slide that 
contains both enlarged, multinucleated cells and un-enlarged cells, and that have 
either taken up or excluded the dye. 
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Figure 3: A population of viable and non-viable cytochalasin B treated 
U937 leukemia cells.  
 
 
Measuring cell size 
 
 The size distribution of the cell suspension was determined using the 
Coulter Counter.  The Coulter Counter is an instrument designed to analyze 
particle size by calculating the measurable changes in electrical resistance 
produced by nonconductive particles suspended in an electrolyte.  Using a small 
round-bottomed cuvette, 1 ml of cell suspension was added to 14 ml of isotone for 
a dilution factor of 15.  A blank was also prepared with 15 ml of isotone and was 
run first before the samples to ensure that the background particle count was low.  
The instrument was set at a desired particle threshold to obtain the number of cells 
that are equal to or bigger than the setting (for example, ≥19 µ finds the total 
number of cells that are at least 19 µ.)  The aperture tube was flushed between 
each analysis and the sample was gently stirred with a glass rod to evenly re-
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suspend the cells, but to avoid damaging the cells or getting air bubbles.  A 0.5 ml 
sample was counted.  The cell number per ml was determined by multiplying the 
particle count by 2 and by the dilution factor.  Dr. Thomas Fondy developed 
Coulter Count forms using Microsoft Excel (see Appendix B), which allowed us 
to determine the number of cells at each increasing micron from 10 µ to 30 µ and 
also calculate the percentages of cells of various diameters.   
  
 
Determining nuclear content 
 
 
 The number of nuclei in a cell was determined by DAPI (4', 6-Diamidino-
2-phenylindole) staining techniques.  The DAPI stain was used because it could 
form fluorescent complexes with natural double-stranded DNA.  The procedure 
involved mixing 1 ml of cells at a density of 1x10
5 
cells/ml with 0.5 ml of 10% 
formalin solution. Formalin was used because it has the ability to kill and fix the 
cells so that they would maintain their shape and structure without loss of nuclear 
content.  The cells were left in the formalin overnight, and the next day the 
suspension was centrifuged for 90 seconds at 1,500 RPMs, or 500 G.  Care was 
taken not to exceed 2,100 RPM because this may damage the cellular integrity.  
The cells appeared as a small pellet on the bottom of the microfuge tube.  The 
supernatant was removed and 5 µl of DAPI (concentration 1 µg /µl) was added to 
the pellet.  After being carefully mixed, 5 µl of the cells in the DAPI suspension 
were added to a slide and the slide was sealed with a cover slip.  Under a 
fluorescent microscope, the number of nuclei in each cell was recorded.  Figures 4 
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and 5 show visual differences in the number of nuclei seen in both small, 
mononuclear U937 cells and enlarged, multinucleated U937 cells. 
 
 
 
 
 
 
 
 
 
 
Figure 4: U937 leukemia cells that have been enlarged and multinucleated by 
treatment with cytochalasin B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Control mononucleated U937 leukemia cells. 
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RESULTS  
 
Separation of the enlarged, multinucleated cells 
  
The effectiveness of the separation technique using the 20 µ nylon mesh 
sieve was determined by measuring the percentage of all trapped •19 µ cells in 
comparison with the percentage of all •19 µ cells in the unseparated population 
and in the nylon mesh filtrate.  The percentages of total cells sieved that were 
recovered in the trapped and filtrate fractions were determined in a recovery 
analysis.   The dye exclusion viability and extent of multinucleation were 
determined for the trapped fraction.  The cell sizing and counting were done using 
a Coulter Counter and hemocytometer (see Methods).  Before the cell suspension 
was sieved, the proportion of cells that were •19 µ was 67%, as seen in Table 1 
and Figure 6, and the trypan blue viability was 77%.  After the filtration, the 
proportion of cells •19 µ in the filtrate was reduced to 52%.  This population was 
74% of the total sieved.  The trapped cells showed 44% of the cells were •20 µ.  A 
Coulter count at 19 µ was not done for the trapped cells.  The trapped portion 
showed 82% trypan blue viability.  Of the viable cells, 93% were enlarged      (•20 
µ).  Thirteen percent of the total cells sieved were recovered in the trapped 
fraction.  The total recovery in the filtrate and trapped fractions was 87%.  This 
data can be seen in Table 1 below.           
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Table 1:  20 µ Nylon Mesh Separation of CB-Treated U937 Leukemia Cells 
               (1.0 µM CB, 3 days, 10% FBS Medium) 
 
Fraction Volume 
(ml) 
Total 
Cells/ml 
(in 104 
units) 
Total 
Cells (in 
104 units) 
Recovery       
(%) 
Trypan 
Blue 
Viability 
Cells 15 µ to 
19 µ (% of 
Total) 
Cells >19 
µ (% of 
Total) 
Cells 
>25 µ 
(% of 
Total) 
Unseparated 
 
22.5 1.8 40.5 100 77% 33 67 26 
Filtrate ~30 1.0 30 74.1 ----- 48 52 19 
Sieve 
Trapped 
~13 0.4 5.2 12.8 82% 56 44 37 
 
 The trapped fraction from the sieve contained a higher percentage of the 
biggest cells (>25 µ) than the filtered fraction, as seen in Table 1 and Figure 6.  
Thus, the nylon mesh sieve did preferentially trap the bigger enlarged cells.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Percent of total cells >14 µ of the unseparated CB-treated U937 
leukemia cells and the trapped and filtered fractions after sieve separation. 
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Ultrasonic disruption of the U937 leukemia cells 
 
 To determine whether there was a sonic sensitivity in cells treated with 
cytochalasin B, control U937 cells and CB-treated U937 cells, taken from the  
>19 µ trapped fraction after separation, were exposed in duplicate to ultrasound at 
a power of 0.77 watts for varying lengths of time, specifically, 0, 2, 4, 6, 8, and 10 
seconds (only one tube was exposed to 10 seconds).  The data for the CB-treated 
cells can be seen in Appendix C.  (The controls are not listed.)  Data are shown 
for 0, 2, 4, 6, 9, and 11 days post-sonication; however, both CB-treated tubes 
sonicated at four seconds and the single CB-treated tube sonicated for ten seconds 
could not be counted at 11 days due to mold growth.  In addition, one tube at four 
seconds and one tube at ten seconds for the controls had mold growth by day 9, so 
the data used is only for one tube at day 9.  The controls reached confluency by 
day 6 and the CB-treated cells reached confluency by day 11, so the effect of late-
stage mold growth in these tubes is of minor importance.   
In the regrowth counts for the CB-treated enlarged cells, by day 9, the 
proportion of cells that were >19 µ were between 2% and 14%.  By day 11, no 
viable big cells were seen in the 0, 2, 6, and 8 second tubes, the tubes that had no 
mold growth.  This can be seen in Figure 7. 
 
 
 
 
 
 
 
24 
 
 
 
 
 
 
 
 
 
Figure 7: Percent of Big Cells Post Sonication. 
 
As seen in Figure 7 and Appendix C, the percent of the total enlarged, big 
cells for the CB-treated tubes decreased overall as a function of the length of time 
(in days) post-sonication.  As the number of elapsed days after sonication 
increased, the initial viable big cells either died or may have turned into small 
cells due to cell division.  By day 9, the average percent of trypan blue positive 
(dead) enlarged cells was 58%, compared with 11% for day 2.  The few viable big 
cells seen on day 9 could have been mitotic cells that were dinucleated and 
enlarged; normal U937 leukemia cells typically have around 3% of their cells 
enlarged due to mitosis.   
 After the tubes were sonicated at their respective time intervals on day 0, 
the initial day 0 counts were determined as the initial reference point for later 
regrowth counts, and also to determine whether sonication affected cell size 
distribution, especially in the enlarged CB-treated tubes.  As seen in Figure 8, 
there was a fairly consistent effect on the number of big viable cells per milliliter 
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immediately after sonication.  While the number of big cells per milliliter did 
decrease from 0 seconds of sonication (i.e. no sonication) to 6 seconds and they 
increased again from 6 to 10 seconds of sonication, showing no clear trend.  
However, combining all nine sonicated tubes versus the non-sonicated, 0 second 
tubes shows an average of a 71% decrease of big viable cells per milliliter as a 
result of sonication, suggesting that there was an effect. 
   
 
 
 
 
 
 
 
Figure 8: Viable Big Cells Immediately After Bath Sonication. 
 
In addition to decreasing the proportion of big viable cells, sonication also 
affected the subsequent growth rate of the CB-treated cells.  The cell counts at 
day 2, most notably, seem to show that the growth of the viable cells was 
progressively inhibited by increasing the time of sonication.  This can be seen 
more clearly in Table 2, which tabulates the number of cells per milliliter on day 
two as a function of the amount of sonication.  The growth rate of the cells does 
decrease as the amount of sonication is progressively increased, reaching a 
maximum 76% retardation of growth at six seconds.   
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Table 2:  Day 2 Regrowth Counts showing the retardation in the growth rate 
 
 
Amount of Sonication  
(secs) 
Viable cells/ml  
in 10^4 units 
% of 0 secs growth rate 
 
Amount of growth rate  
retardation (%) 
0 6.56 ------- 
-------- 
2 6 91 
9 
4 4.78 73 
27 
6 1.56 24 
76 
8 2 30 
70 
10 3.56 54 
46 
 
Figures 9 and 10 show logarithmic plots of the concentration of viable 
cells from the CB-treated tubes and for the control cells for different amounts of 
sonication.  Comparing the two figures, there seems to be a retardation in growth 
rate for the CB-treated tubes that persisted throughout the period of observation.  
Both the non-sonicated CB-treated cells and the non-sonicated control cells grew 
to confluency, but the control cells reached this point roughly four days earlier 
(day 6) than the CB-treated cells (~day 11).  This delay in reaching confluency 
shows that enlarged purified CB-treated cells retain viability, but have a lower 
growth fraction and/or a longer cycling time than control U937 cells exhibit. This 
is consistent with cloning efficiency determinations by Dr. Thomas Fondy where 
the control U937 cells show 50% cloning efficiency, while the trapped cells show 
a cloning efficiency of 5% to 8%.     
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Figure 9:  Regrowth of the U937 CB-Treated Small Cells after Bath 
Sonication. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Regrowth of the U937 Leukemia Control Cells after Bath 
Sonication. 
The most clear cut evidence of a retardation in growth rate related to the 
amount of sonication can be seen by averaging together the means for 0 and 2 
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seconds and comparing these results to the comparable average means for 6 and 8 
seconds.  (Performing these averages improves the statistical significance of the 
result.)  In Figure 11 which plots the growth after sonication of the control 
leukemia cells, there is no statistically significant difference between the average 
of the means of the number of viable cells per milliliter of the 0 and 2 second 
tubes versus the average of the means of the 6 and 8 second tubes.   
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Regrowth after Sonication of Control U937 Leukemia Cells, 
0 & 2 secs vs 6 & 8 secs Tubes. 
 
However, when the same comparison is made with the CB-treated 
leukemia cells in Figure 12, a statistically significant difference can be seen 
between the means of the 0 and 2 second data versus the means of the 6 and 8 
second data, based on t-tests that were performed on the data for each observation 
time.  The differences on days 2 and 6 are statistically significant at  p-value= 
 
 
29 
0.005 and p-value= 0.02, respectively (Day 2 t-statistic=4.09, Day 6 t-
statistic=3.04, df= 6).  Days 4 and 9 are not statistically significant.  Data at day 
11 was not included due to mold growth, which lessened the sample size.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Regrowth after Sonication of CB-Treated U937 Leukemia Cells,  
0 & 2 secs vs 6 & 8 secs Tubes. 
 
 
Figure 13 plots the total number of dead control U937 leukemia cells as a 
function of days post-sonication.  Examining this figure, and excluding day 11, 
there seems to be no effect of sonication on the control cells after day 0 since the 
percent of dead cells remains approximately constant as a function of time at all 
levels of sonication.  (On day eleven, all the samples show an elevated count of 
dead cells, perhaps because the cells had been at or near confluency for five days.)  
There does, however, seem to be initial damage on the controls, evident by the 
high percentages of trypan blue positive cells on day 0.  Nevertheless, the highest 
percentages of dead cells are in the 2, 8, and 10 second tubes, which only had 11, 
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20, and 24 cells counted in the hemocytometer for 18 fields each, respectively.  
(On later days, there was not a problem of a small sample size because the counts 
were much larger.)  Thus, sonication might have had an initial effect on the 
control cells, but since the samples are so small, it is hard to tell if the effect is 
real.  If it is, it disappeared by day 2 once the cells began growing toward 
confluency.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Percent of Total Dead Control U937 Leukemia Cells as a Function 
of Days Post-Sonication. 
 
The percent of CB-treated dead cells seen in Figure 14 shows a distinct 
difference in the pattern of dead cells compared to the viability of sonicated 
control cells.  Although the CB-treated cells were initially damaged immediately 
after sonication, just as the controls were, beginning at day four, the percent of 
dead CB-treated cells for 8 and 10 seconds of sonication does seem to increase 
and stay relatively higher than the non-sonicated CB-treated cells.  Thus, there 
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does seem to be a slight dose-dependent effect for the sonicated CB-treated cells 
that was not seen in the sonicated control cells.  This higher death rate is also 
consistent with the lower growth rate of the CB-treated cells seen previously in 
Figure 9.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Percent of Total Dead CB-Treated U937 Leukemia Cells as a 
Function of Days Post-Sonication. 
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DISCUSSION AND CONCLUSION 
 
 
Separation of the enlarged, multinucleated cells 
 
 
A great deal has been learned from our separation experiments and we 
have utilized some new ideas to enhance our methods of filtration and purification 
of enlarged multinucleated cells.  In the separation experiment we performed 
using the 20 µ nylon mesh sieve, the trapped fraction contained approximately a 
52:44 ratio of small and big cells, respectively.  Since >50% of the trapped 
fraction was still composed of cells <19 µ, the 20 µ sieve trapped a substantial 
proportion of cells smaller than 20 µ.  This large percentage of small cells trapped 
by the filter may have resulted because big cells blocked the filter holes so the 
small cells could not flow through.  We observed that the cells collected around 
the edges of the mesh filter and were able to obstruct passage.  Some cells larger 
than 20 µ passed through the nylon mesh.  Big cells that were not trapped by the 
filter may have gone through the filter because of its range of hole sizes (20 ± 7 µ) 
or because they were physically forced through it by net hydrodynamic flow.  
Since the big cells have disrupted actin microfilaments, they are likely to be 
deformable.   
The separation technique was a bit more effective for cells that were 
roughly • 25 µ since the trapped fraction contained a larger percentage of 25 µ 
cells than the filtrate did, as seen in Figure 6.  The filtration method was most 
effective for the largest of the big cells (30 µ).  Although the trapped fraction only 
contained 44% enlarged and multinucleated cells, the experiment suggested 
modifications to our sieving procedures that were in fact highly effective.  We 
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have modified many different aspects of the method in developing our improved 
procedure (see Methods) to enhance and maximize the purification.   
The first modification we made is probably the most important change in 
regards to how the cells behave during filtration.  We had previously noticed that 
when the cells were added to the filter, the big cells were forced through the filter 
by hydrodynamic flow.  There also seemed to be many holes in the filter that were 
blocked, suggesting occlusion and termination of flow.  We now allow the cells to 
settle through a continuous volume of phosphate buffered saline while filtrating 
with no net hydrodynamic flow, rather than letting them simply drip through the 
filter in a flowing medium.  To do this, we use a crystallizing dish as a holder and 
place the sieve within it.  With a continuous liquid volume around the sieve, no 
cells are forced through and have the chance to settle through the filter on their 
own with no pressure involved.  Before adding the cells, the sieve is submerged in 
PBS until the liquid level is roughly 1 cm above the top of the sieve.  Once the 
cells are added and begin to settle through the medium, there is no net flow 
through the filter and there is less of a chance for the big cells to be pushed 
through by heavier cells above them. We did observe in the microscope that the 
trapped cells bounced up and down above the sieve perforations and did not 
occlude them.   
Following the adaptation to the sieve apparatus, it occurred to us that the 
procedure could be further improved if it were possible to partially separate the 
cells before they were applied to the sieve.  To do this, we began centrifuging the 
cell suspension at different forces and durations to see what combination gave the 
optimal separation of big and small cells in the precipitate and supernatant.  After 
experimenting with centrifugation of the cells, it was determined that a speed of 
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200 RPM, or 20 G, was the ideal force for a period of 2 minutes.  By centrifuging 
the cells before they are added to the filter, we can preferentially leave the small 
cells behind and concentrate the precipitate with big, multinucleated cells.  Once 
the concentrated cell suspension is added to the filter, it would also be easier to 
see the direct effect of the sieve on the multinucleated cells if there were fewer 
small cells present in the initial cell population added to the sieve. 
Another modification to the filtration method we made was unit gravity 
sedimentation of the cells before they are applied to the filter. The cell suspension 
is first added to a syringe attached with a leur lock valve and then room 
temperature PBS is added on top of the suspension to give the cells a medium to 
settle in.   The syringe is then inverted to allow the big cells to settle near the 
plunger, and then the syringe is re-inverted so that the small cells are closest to the 
leur lock valve.  By doing this we can initially separate the cells inside the 
syringe, thus allowing the small cells to come out first after the syringe is re-
inverted and followed by the bigger cells.  We believe that this could help 
improve the efficacy of the separation by allowing the small cells to pass through 
the sieve without being occluded by big cells.  This unit gravity separation using a 
syringe can be used in conjunction with the centrifugation, or by itself, to 
preferentially separate the cells before filtration. 
Another adjustment we made to our procedure was in the filter that was 
used to separate the cells.  The filter originally used was a 20 µ nylon mesh sieve 
followed later with a 20 µ stainless steel mesh sieve.  These filters had margins of 
error of about ± 7 µ.  Thus, there was no guarantee that every perforated hole was 
exactly 20 µ.  Since many of the holes may have been bigger than expected, this 
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could be the reason why some of the big cells were not trapped by the filter.  After 
researching sieves and materials, we found a nickel electroporated sieve that 
promised to give better purification results.  Because the sieve is made by an 
electroporating process that forms uniform holes in a nickel plate, rather than by 
weaving nylon or stainless steel mesh, it has a smaller margin of error (± 2 µ).  
The sieve also has round apertures (round holes) that are not possible with woven 
nylon threads or stainless steel wires.  This provides uniform round perforations 
rather than rectangular openings to enhance purification.      
In addition, we also think that the big cells might have been pushed 
through the filter because the room temperature PBS made the cells’ cytoskeleton 
plastic and allowed the cells to deform without actually rupturing.  To modify this 
and make the cells remain rigid, we now conduct the sieve purification at 4˚C.  
Lastly, we have observed that when adding cold PBS to the sterile sieve, bubbles 
could collect underneath it.  If this happened, many holes of the sieve were 
blocked and unable to let cells flow through them, as evidenced by microscopy. 
We now sterilize the sieve in distilled water to keep it wet.  Before sieving the 
cells, we pour off the water and add cold PBS to the sieve in the crystallizing dish 
tipped to one side.  This prevents any air bubbles from blocking the underside of 
the sieve.  With all these modifications made, our procedure has allowed us to 
produce a population of CB-treated U937 leukemia cells that are 94% •19 µ cells.   
 
 
 
Ultrasonic disruption of the U937 leukemia cells 
 
 
In our work, we attempted to exploit the enlarged size, weakened 
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cytoskeleton, and consequent increase in membrane fragility of CB-treated cells 
versus control cells in producing increased sonic damage to CB-treated leukemia 
cells.  Previously, Dr. Thomas Fondy had found that Coulter counts showed a 
shift in size distribution of the CB-treated cells to smaller cells post-sonication 
(see Appendix D).  In the present study, we have observed a similar effect of 
sonication on cell size (Figure 7).  We also found that there was a statistically 
significant inhibition of growth in sonicated CB-treated cells at two and six days 
post-sonication in comparison with CB-treated cells not sonicated or given two 
seconds of sonication.  However, further experiments would need to be completed 
to determine whether the growth inhibition and shift in size distribution found in 
the CB-treated cell population is reproducible and different from the effects of 
sonication on the control U937 leukemia cells. 
Based on t-tests that were performed to assess whether the average means 
of the number of viable cells per milliliter for the combined 0 and 2 seconds data 
were statistically different from the combined 6 and 8 seconds data, we can say 
with 99.5% confidence that the average means of the 0 and 2 second data at day 2 
for the sonicated CB-treated cells were statistically different from the average 
means of the 6 and 8 second data on the same day.  In addition, the difference 
between the average means at day 6 was statistically significant at the 98% 
confidence level.  Although the difference between the two data sets on day 4 was 
not statistically significant (p-value= 0.10), the data shows that there was a true 
retardation effect on the growth rate of the CB-treated cells by the sonication.   
Since there was no statistically significant difference seen on any day for the 
control data, we can be reasonably confident that there is a difference in sonic 
sensitivity of CB-treated enlarged cells in comparison with control U937 
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leukemia cells.   
In addition, we observed that the percent of viable big cells was reduced as 
additional days passed following the sonication, compared to non-sonicated CB-
treated tubes.  Since the percentage of trypan blue positive big cells remained at 
around 10% or higher for up to six days, it is likely that sonication killed some of 
the enlarged CB-treated cells or split them into smaller cells.  Viable enlarged 
cells would be expected to divide in the absence of CB.  This is consistent with 
the reduction in cell size distribution as a function of sonication seen on day 0. 
In our experiment we took data only every second day, and there was a 
three-day interval after day 6.  It would improve the experiment if counts were 
taken at shorter intervals in order to determine when in fact, all the big viable cells 
disappear for each length of time that the tubes were sonicated.   With more 
readings at shorter time intervals, an exact point of complete big cell 
disappearance could be determined, which could make it easier to see if there 
really is a clear effect that correlates with the amount of sonication.  In addition, 
the big cells should be observed individually by microscopic analysis to 
determine the proportion that are dividing and returning to normal-sized leukemia 
cells (i.e. are clonogenic) versus the proportion that have been killed by sonication 
(i.e. are not clonogenic).  With more refined observations of individual cells, we 
could determine what is causing the big cells to be depleted in number.  
The cells from the CB-treated population showed a four-day delay in 
growth compared to the control cells.  It appears, though, that they grew similarly 
to the control cells after that, both reaching a point of confluency, although the 
control cells reached that point roughly four days earlier than the CB-treated cells.  
Despite the shift in growth rate, the small cells seemed to behave like the control 
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cells that were never treated with CB.  Whether they really do resemble control 
cells in other features is not known.  Since the cycle time in 20% FBS medium is 
about 18 hours, a four-day difference in growth rate represents 5.3 doublings.  
This indicates an 80% difference in cell viability or a slower cell cycle time for 
the CB-treated enlarged, purified cells versus the control U937 leukemia cells.   
Other characteristics of these CB-treated small cells would be of interest 
as well.  For instance, do they resist becoming enlarged when treated with a 
second exposure to CB or do they represent a distinct sub-population of U937 
cells with some innate feature that prevents them from enlarging and 
multinucleating?  Even though the leukemia cells all come from the same U937 
human promyleocytic cell line, stable sub-populations could exist that respond 
differently to CB.  U937 leukemia forms several different types of differentiated 
hematopoietic cell clones in agarose that could arise from different cell sub-
populations.  Further experiments into the properties of these cells need to be 
performed in order to fully understand their differences.    
One significant problem that was encountered in the experiment was mold 
contamination in a few tubes at the late stages of regrowth.  If initial mold growth 
began as early as day 6 but did not become evident until day 9, the mold growth 
could affect results in certain tubes showing anomalous growth.  Agarose cloning, 
by Dr. Thomas Fondy, of the 23 tubes showed mold growth in only two of the 
tubes, and this growth appeared 15 days after seeding, demonstrating that mold 
contamination on day 0 was not a problem.  Contamination could have been 
introduced into some regrowth tubes during the process of multiple sampling on 
days 2, 4, 6, and 9.  Without late stage mold contamination in some tubes, the 
experiment could have been followed for additional days.  However, the key 
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observations had already been made by day 9, so late stage mold growth in some 
tubes was apparently only of minor consequence.  
One major limitation of our experiment was that we performed the 
sonication with an ultrasonic bath cleaner designed to clean laboratory 
instruments.  In future experiments, it would be best to use a more reliable source 
of ultrasound that has a power output that can be modulated and can provide 
consistent levels of acoustic cavitation.  We calculated the power output of the 
ultrasound bath using Fourier’s law of thermal conduction based on the 
temperature difference caused by the sonication and the amount of time sonicated 
(see Appendix E).  Using a more precise instrument with a known power output 
and cavitation that can be varied would be costly, but it would make the results 
more reliable and allow us to investigate sonic effects at levels less than 0.77 
watts that were employed in the current experiment. This would permit a test of 
longer sonication times without raising the temperature to the point where thermal 
effects directly destroy the cells.  If the intensity of the ultrasound could be varied 
in a systematic way, it might also be possible to find the threshold intensity for 
immediate disruption of the large cells.  
Overall, the data demonstrate some effects that correlate directly with the 
amount of sonication that was applied to the CB-treated U937 leukemia cells and 
that were not displayed in the control cells.  Two examples are the statistically 
significant inhibited growth rate at days 2 and 6 as well as a difference in the non-
sonicated versus sonicated CB-treated cells with respect to the percent of trypan 
blue dead cells.  One way to definitively demonstrate an effect would be to look 
for a level of sonication that has a clear-cut effect on the controls and compare 
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that to effects on the CB-treated cells.  It is hypothesized that if a strong enough 
amount of sonication is used for a long period of time, all cells would be killed.  
 If a differential effect of sonication on the CB-treated cells in comparison 
with non CB-treated leukemia cells can be confirmed, this could potentially 
introduce ultrasound as a physical modality in leukemia treatment. The sonication 
could be combined with other physical and chemical modalities to potentially 
enhance and increase the cytotoxic effects of microfilament agents in treatment in 
pre-clinical animal models.  For example, we are proposing that sonication may 
have enhanced effects on enlarged CB-treated cells under hyperthermic 
conditions, in hypotonic medium, or if the cells are treated with microtubule-
directed agents that may render the enlarged cells even more sensitive to sonic 
cavitation. 
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Appendix A 
 
 Cell Viability form 
 
 
Trypan Blue Cell 
Counting Form                     
Cell Reading Date:  Raw Correct  Raw Correct  Raw Correct  Raw Correct         
Conditions:  Count/ Count/ Cells/ Count/ Count/ Cells/ Count/ Count/ Cells/ Count/ Count/ Cells/ Total Raw Total Total Total % % 
 Fields Fields Fields 0.1 Fields Fields 0.1 Fields Fields 0.1 Fields Fields 0.1 Raw Cts Correct Cells/ Viable Viable Viable 
 Count Count Count mm3 Count Count mm3 Count Count mm3 Count Count mm3 Cts/ Add Count/ 0.1 Cells/  Cells 
X Cells/0.1mm3 = X 
cellx10E4/ml TB- TB- TB- TB- TB- TB- TB+ TB+ TB+ TB+ TB+ TB+ Fields Check Fields mm3 0.1  Big 
Sample Being 
Counted  Large Large Large Small Small Small Large Large Large Small Small Small Count  Count  mm3   
1                     
2                     
3                     
4                     
5                     
6                     
7                     
8                     
9                     
10                     
11                     
12                     
13                     
14                     
15                     
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Appendix B  
  
   Coulter Count form 
 
 
Coulter 
Gate
Mean 
Isotone 
Counts
Sample 
Counts 
Reading 1
Sample 
Counts 
Reading 2
Sample 
Counts 
Reading 3
Sample 
Mean 
Counts
Cts - 
Isotone
Step - Next 
Step 
% of Cells 
13u or 
greater
Number of 
Cells 
(Count X 2 
X Dilution 
Factor
10 u
12 u
13 u
14 u
15u
16u
17 u
18 u
19 u
20 u
22 u
24 u
26 u
28 u
30 u
Sum 13 u or greater:
Sum 13 to 18 u 
Sum 19 to 28 u
Total Cells 13 u or Greater/ml (in 10E4 units)
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Appendix C  
  
Raw Data for the Sonication of the CB-Treated U937 Leukemia  
Cells taken from 19 µ Steel Mesh Separation (1.25 µM CB, 36 hours, 20% 
FBS Medium) 
 
Tube # of Viable 
Small Cells
% Total Viable 
Big
0 9 3 12 75
2 18 41 59 32
 0 secs 4 17 70 87 20
6 7 125 132 6
9 2 129 131 2
11 0 89 89 0
0 4 10 14 29
2 23 31 54 47
 2 secs 4 10 39 49 22
6 17 94 111 16
9 2 184 186 1
11 0 88 88 0
0 3 4 7 43
2 12 31 43 26
4 secs 4 4 39 43 10
6 6 66 72 9
9 9 202 211 5
11 ----- ----- ----- -----
0 2 5 7 29
2 4 10 14 31
6 secs 4 11 24 35 31
6 4 50 54 6
9 5 188 193 3
11 0 63 63 0
0 5 1 6 75
2 3 15 18 17
8 secs 4 2 20 22 7
6 5 52 57 9
9 6 181 187 3
11 0 95 95 0
0 10 3 13 77
2 5 27 32 15
10 secs 4 14 38 52 27
6 12 128 140 9
9 1 183 184 1
11 ----- ----- ----- -----
Days after 
Sonication
# of Viable Big 
Cells
# of Total 
Viable Cells
 
 
 
 
 
46 
Appendix D  
 
 Distribution of cell sizes post-sonication 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix F 
 
Power Output for the Sonicator Bath 
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  Power Output for Sonicator Bath 
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P= Output power 
ρ=density of water = 1 g/ml 
V=volume in test tube = 2 ml 
Cv = specific heat of the water at constant volume = 4.186 J/(g°C) 
T=temperature difference 
t = time sonicated 
Power Output for Sonicator Bath
0.5
0.55
0.6
0.65
0.7
0.75
0.8
0.85
0.9
0.95
1
0 2 4 6 8 10 12
Seconds of Sonication
W
a
tt
s 
(±
 S
td
 E
rr
o
r)
n = 5
2 ml Distilled Water in
8 ml in 10 mm Diameter Tube.
250 ml Distilled Water in Bath
Mean for n = 25; 0.768
Range: 0.42 to 1.05
Std Dev: 0.166
Std Error: 0.033
